Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma
Zachary J. Brown, Jordan M. Cloyd
Abstract
For patients with localized pancreatic cancer, neoadjuvant therapy (NT) is increasingly delivered before surgery to maximize the receipt of multimodality therapy and the odds of a margin-negative resection. Three decades of refining the use of NT have led to its acceptance as a valid treatment approach for pancreatic adenocarcinoma. In this review, we discuss the rationale for and recent global trends in the utilization of NT for patients with pancreatic cancer.
Topics & Concepts
MedicinePancreatic ductal adenocarcinomaNeoadjuvant therapyPancreatic cancerAdenocarcinomaReceiptOncologyPancreatectomyGeneral surgeryResectionInternal medicineCancerSurgeryBreast cancerComputer scienceWorld Wide WebPancreatic and Hepatic Oncology ResearchNeuroendocrine Tumor Research AdvancesPancreatitis Pathology and Treatment